Theralizumab Biosimilar - Research Grade

Huang et al. A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity. J Transl Med, 2023, 21, 346.

Human

CD28

5mg/ml

Human IgG4

CHO cells

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Functional Assays

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Detects human CD28. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Theralizumab.

Blue ice

CD28 is the principal co-stimulatory receptor that provides the second signal for T-cell activation and is foundational to immunology research. This research-grade reagent is an unconjugated, non-therapeutic analog of theralizumab directed at human CD28 and validated for functional assays. It is supplied for research use only in a low-endotoxin format suitable for in vivo studies and manufactured in scalable milligram to gram quantities for bulk and high-throughput laboratories. Typical uses include co-stimulatory signalling assays, T-cell activation studies, in vitro screening, in vivo immune models, and reference applications in biologics characterisation.

TGN1412, CD28-SuperMAB, TAB08

P10747

ICH3002

https://www.imgt.org/mAb-DB/